The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis

Description: Recent studies suggest that blockade of the NLRP3 (cryopyrin) inflammasome interleukin 1β (IL1β) pathway may offer a new treatment strategy for gout.
Conclusions: This proof-of-concept study demonstrated that rilonacept is generally well tolerated and may offer therapeutic benefit in reducing pain in patients with chronic refractory gouty arthritis
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study R Terkeltaub, J S Sundy, H R Schumacher, F Murphy, S Bookbinder, S Biedermann, R Wu, S Mellis, A Radin Annals of the Rheumatic Diseases 2009;68:1613-1617 full text